{"id":"dbi-102","_chembl":null,"_dailymed":null,"_scrapedAt":"2026-03-28T03:31:29.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123818,"model":"claude-sonnet-4-5-20250929"},"description":"DBI-102 is an investigational therapeutic agent being developed by DermBiont, Inc. currently in Phase 2 clinical trials. The drug's molecular target, mechanism of action, and specific therapeutic indications have not been publicly disclosed, though the company name suggests a focus on dermatological applications.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT05511948","phase":"PHASE2","title":"Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos","status":"COMPLETED","sponsor":"DermBiont, Inc.","startDate":"2022-08-18","conditions":"Hyperpigmentation","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DBI-102","genericName":"DBI-102","companyName":"DermBiont, Inc.","companyId":"dermbiont-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}